Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 14Terminated 8Withdrawn 3Recruiting 2Active not recruiting 2Unknown 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Thyroid Carcinoma, Anaplastic 1Neoplasms 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 17Biopsy 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 9venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3fludarabine 3durvalumab 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Gemcitabine 3Cisplatin 3Carboplatin 3zanubrutinib 2prednylidene 2deltacortene 2aldesleukin 2Vincristine 2Taxes 2Stem Cell Transplantation 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Protein Subunit Vaccines 2Prednisone 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × dabrafenib × Clear all
NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

JS InnoPharm, LLC

Phase 1 Suspended
71 enrolled
DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡